SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 177 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $58,080,000 | -14.9% | 4,000,000 | +22.6% | 9.50% | +1.2% |
| Q2 2023 | $68,273,744 | +0.8% | 3,262,004 | +1.7% | 9.39% | +7.4% |
| Q1 2023 | $67,710,424 | +3.9% | 3,205,986 | +25.2% | 8.74% | -12.6% |
| Q4 2022 | $65,182,209 | +19.3% | 2,561,187 | +12.7% | 10.00% | -13.1% |
| Q3 2022 | $54,618,000 | +13.0% | 2,272,915 | -9.5% | 11.51% | -6.8% |
| Q2 2022 | $48,335,000 | +43.9% | 2,512,240 | +30.0% | 12.34% | +13.3% |
| Q1 2022 | $33,592,000 | +60.5% | 1,932,800 | +102.1% | 10.90% | -2.6% |
| Q4 2021 | $20,930,000 | – | 956,165 | – | 11.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |